Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for

Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring
Committee for Pivotal Phase lll Clinical Trial for Firdapse(TM)

CORAL GABLES, Fla., March 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neuromuscular and neurological diseases and disorders, announced
today that, on March 25, 2013, the independent Data Monitoring Committee (DMC)
overseeing the Company's ongoing pivotal Phase III clinical trial in the
United States and Europe evaluating Firdapse™ for the treatment of
Lambert-Easton Myasthenic Syndrome (LEMS) recommended that the Company
continue the trial as planned based on the committee's review of safety and
clinical data from the trial.

The DMC is a group of experts responsible for the independent review of
accumulated clinical safety and efficacy data obtained in our clinical trial,
in order to safeguard the interests and safety of participants and future
patients. The DMC considers study-specific data, as well as relevant
background knowledge about the disease, test agent or patient population under
study.

The Firdapse™ Phase III clinical trial is designed as a randomized,
double-blind, placebo-controlled, discontinuation trial enrolling 30 patients
diagnosed with LEMS at sites in the U.S. and Europe. Catalyst anticipates that
it will be adding up to 20 additional sites in the U.S., Europe, Canada and
South America. Catalyst expects to complete enrollment in the trial by the end
of the fourth quarter of 2013 and to announce top line data from the trial
during the second quarter of 2014.

About LEMS

Lambert-Eaton Myasthenic Syndrome, or LEMS, is a rare autoimmune disorder
characterized by muscle weakness of the limbs. The disease is caused by an
autoimmune reaction where antibodies are formed against the connection between
nerves and the muscles they supply. Often, LEMS is associated with an
underlying malignancy, most commonly small-cell lung cancer, and in some
individuals, LEMS is the first symptom of such malignancy. LEMS generally
affects the extremities, especially the legs. As the disease most affects the
parts of limbs closest to the trunk, difficulties with climbing stairs or
rising from a sitting position are commonly noted. Physical exercise and high
temperatures tend to worsen the symptoms. Other symptoms occasionally seen
include weakness of the muscles of the mouth, throat, and eyes.Individuals
affected with LEMS also may have a disruption of the autonomic nervous system,
including dry mouth, constipation, blurred vision, impaired sweating, and/or
hypotension.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company
focused on the development and commercialization of prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases and disorders,
including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and
Tourette's Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of
LEMS, is currently undergoing testing in a global, multi-center, pivotal phase
III trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115) to treat infantile spasms, and
epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's Syndrome,
and movement disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
the Company's actual results in future periods to differ materially from
forecasted results. A number of factors, including whether the Phase III trial
will be successful, the Phase III trial will be completed in the schedule
described above, any of the Company's product candidates will ever be approved
for commercialization, as well as those factors described in the Company's
filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect the Company. Copies of the Company's filings with the SEC are
available from the SEC, may be found on the Company's website or may be
obtained upon request from the Company. The Company does not undertake any
obligation to update the information contained herein, which speaks only as of
this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
 
Press spacebar to pause and continue. Press esc to stop.